Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN (MJIRI)   2018 , Volume 32 , Number 1; Page(s) 0 To 0.
 
Paper: 

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia

 
DOI: 

10.14196/mjiri.32.36

 
Author(s):  AMINIMOGHADDAM SOHEILA*, Nezhadisalami Forough, ANJIDANI SHABNAM, Barzin Tond Saeedeh
 
* Department of Gynecology and Oncology, Iran University of Medical Sciences, Tehran, Iran
 
Abstract: 
Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients’ outcome. Methods: Hospital charts of all patients with confirmed diagnosis of high-risk GTN who received EMA/EP regimen treatment during a 12-year period (2001-2012) at the tertiary center of comprehensive women's hospital in Tehran, Iran, were reviewed from 2012 to 2013, retrospectively. Results: In this study, 25 patients with GTN who were treated with EMA/EP regimen during the study were identified. Complete remission rate in GTN patients with failure of single agent chemotherapy who were treated with EMA/EP regimen, as the first-line treatment, was 100%, while it was 81% in those with primary high-risk GTN. Overall remission rate in high-risk GTN patients treated with EMA/EP regimen was 88%. Anemia (92%) and leucopenia (72%) were the most common adverse effects of EMA/EP chemotherapy regimen. Acute myeloid leukemia (AML) and mortality, as the most severe adverse effects of EMA/EP regimen, were seen only in 1 patient. Conclusion: According to the results, EMA/EP regimen could induce complete remission in 88% of patients with high-risk GTN. Application of EMA/EP is recommended as the first-line therapy in patients with failure of single agent chemotherapy. However, proper care should be considered to prevent and reduce EMA/EP hematologic toxicity.
 
Keyword(s): EMA/EP regimen,Chemotherapy,Gestational trophoblastic neoplasia
 
References: 
 
  pdf-File tarjomyar Yearly Visit 46
 
Latest on Blog
Enter SID Blog